tiprankstipranks
International Stem Cell (ISCO)
OTHER OTC:ISCO

International Stem Cell Stock Analysis & Ratings

ISCO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.31 - $0.79
Previous Close$0.37
Volume200.00
Average Volume (3M)3.25K
Market CapN/A
Enterprise ValueN/A
P/E Ratio-9.8
Beta-0.86
Next EarningsMay 17, 2019
EPS ForecastN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
Smart ScoreN/A


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ISCO FAQ

What was International Stem Cell’s price range in the past 12 months?
International Stem Cell lowest stock price was $0.31 and its highest was $0.79 in the past 12 months.
    What is International Stem Cell’s market cap?
    Currently, no data Available
    What is International Stem Cell’s price target?
    Currently, no data Available
    What do analysts say about International Stem Cell?
    Not enough analysts have published a price target to provide an average price target.
    When is International Stem Cell’s upcoming earnings report date?
    International Stem Cell’s upcoming earnings report date is May 17, 2019 which is 1145 days ago.
      How were International Stem Cell’s earnings last quarter?
      International Stem Cell released its earnings results on Apr 15, 2019. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.12.
        Is International Stem Cell overvalued?
        According to Wall Street analysts International Stem Cell’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does International Stem Cell pay dividends?
          International Stem Cell does not currently pay dividends.
          What is International Stem Cell’s EPS estimate?
          International Stem Cell’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does International Stem Cell have?
          International Stem Cell has 8,004,389 shares outstanding.
            What happened to International Stem Cell’s price movement after its last earnings report?
            International Stem Cell reported an EPS of -$0.12 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
              Which hedge fund is a major shareholder of International Stem Cell?
              Currently, no hedge funds are holding shares in ISCO

              ---

              International Stem Cell Stock Analysis

              Smart Score
              N/A
              Not Ranked
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10
              Price Target
              No data currently available
              This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
              Learn more about TipRanks Smart Score

              Company Description

              International Stem Cell

              International Stem Cell Corp. is a clinical stage biotechnology company, which engages in the development of therapeutic and biomedical products. It operates through the following segments: Cosmetic Market, Biomedical Market, and Therapeutic Market. The Cosmetic Market segment develops, manufactures, and markets a cosmetic skin care products based on the company's proprietary parthenogenetic stem cell technology and targeted small molecule technology. The Biomedical Market segment involves in the development, manufacture, and commercialization of primary human cell research products. The Therapeutic Market segment focuses on the research and development of human parthenogenetic stem cells for the treatment of diseases of the central nervous system, liver diseases, and is currently conducting clinical trials for the treatment of Parkinson's disease. The company was founded by William B. Adams, Kenneth C. Aldrich, and Gregory S. Keller on August 17, 2001 and is headquartered in Carlsbad, CA.

              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              ThermoGenesis Holdings
              Aethlon Medical
              Quoin Pharmaceuticals
              Cerus
              Cytosorbents

              Popular Stocks

              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis